| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S88610-5mg |
99.10% | ￥210.00 |
>10 | - | - | - | - |
|
S88610-10mg |
99.10% | ￥340.00 |
>10 | - | - | - | - |
|
S88610-25mg |
99.10% | ￥650.00 |
10 | - | - | - | - |
|
S88610-50mg |
99.10% | ￥780.00 |
3 | - | - | - | - |
|
S88610-100mg |
≥98% | ￥1320.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | TH-257 is a potent inhibitor of LIMK1 and LIMK2 with IC50 values of 84 nM and 39 nM for LIMK1 and LIMK2, respectively, and it can be used as a chemical probe for LIMK1 and LIMK2. TH-257 is an allosteric inhibitor targeting a binding pocket induced by an αC and DFG-out conformation. TH257 is exquisitely selective and no significant activity against the wider kinome has been observed in the KINOMEscan assay at 1 μM | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | LIMK1:84 nM (IC50);LIMK2:39 nM (IC50);LIMKinase | ||||||||||||||||||||
| 体外研究： | TH-257 exhibits good biochemical and cellular potencies. But its extremely rapid in vitro clearance renders it unsuitable as a potential in vivo tool | ||||||||||||||||||||
| 参考文献： | 1. Manetti F. Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials. Eur J Med Chem. 2018 Jul 15;155:445-458. 2. Collins R, et, al. Comparative Analysis of Small-Molecule LIMK1/2 Inhibitors: Chemical Synthesis, Biochemistry, and Cellular Activity. J Med Chem. 2022 Oct 27;65(20):13705-13713. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20°C | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京